Wedbush Equities Analysts Raise Earnings Estimates for STOK

Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Analysts at Wedbush increased their Q1 2025 EPS estimates for Stoke Therapeutics in a research note issued to investors on Tuesday, January 7th. Wedbush analyst L. Chico now anticipates that the company will post earnings of ($0.56) per share for the quarter, up from their prior forecast of ($0.59). The consensus estimate for Stoke Therapeutics' current full-year earnings is ($2.03) per share. Wedbush also issued estimates for Stoke Therapeutics' Q2 2025 earnings at ($0.49) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($2.08) EPS, FY2026 earnings at ($2.32) EPS, FY2027 earnings at ($2.53) EPS and FY2028 earnings at ($2.27) EPS.

Other equities analysts also recently issued reports about the stock. Leerink Partnrs raised shares of Stoke Therapeutics to a "strong-buy" rating in a research note on Friday, October 11th. Leerink Partners initiated coverage on Stoke Therapeutics in a report on Monday, October 14th. They set an "outperform" rating and a $18.00 target price on the stock. Cantor Fitzgerald restated an "overweight" rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. HC Wainwright reissued a "buy" rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday. Finally, Chardan Capital assumed coverage on Stoke Therapeutics in a report on Friday, December 20th. They set a "buy" rating and a $24.00 price target on the stock. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Buy" and an average price target of $21.29.

Stoke Therapeutics Trading Up 0.4 %

STOK stock traded up $0.04 during midday trading on Friday, reaching $9.00. The stock had a trading volume of 1,608,920 shares, compared to its average volume of 1,094,717. Stoke Therapeutics has a 52-week low of $4.09 and a 52-week high of $17.58. The company's fifty day simple moving average is $11.98 and its 200 day simple moving average is $13.08. The company has a market cap of $476.70 million, a price-to-earnings ratio of -4.29 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, beating analysts' consensus estimates of ($0.52) by $0.05. The business had revenue of $4.89 million during the quarter, compared to analysts' expectations of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 13,666 shares of Stoke Therapeutics stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $13.61, for a total value of $185,994.26. Following the completion of the transaction, the general counsel now directly owns 21,476 shares of the company's stock, valued at $292,288.36. The trade was a 38.89 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Barry Ticho sold 13,945 shares of the business's stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $12.78, for a total transaction of $178,217.10. Following the sale, the insider now owns 47,332 shares in the company, valued at $604,902.96. This trade represents a 22.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 62,849 shares of company stock worth $809,421 over the last three months. Insiders own 11.30% of the company's stock.

Institutional Investors Weigh In On Stoke Therapeutics

Several large investors have recently added to or reduced their stakes in STOK. Quest Partners LLC purchased a new stake in shares of Stoke Therapeutics during the second quarter worth $29,000. Intech Investment Management LLC acquired a new stake in Stoke Therapeutics in the 3rd quarter valued at about $160,000. The Manufacturers Life Insurance Company boosted its stake in shares of Stoke Therapeutics by 16.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company's stock valued at $189,000 after buying an additional 1,994 shares during the period. Mesirow Financial Investment Management Inc. acquired a new position in shares of Stoke Therapeutics during the third quarter worth about $192,000. Finally, Profund Advisors LLC purchased a new stake in shares of Stoke Therapeutics during the second quarter worth approximately $201,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.